Overview

Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

Status:
Active, not recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of extended dosing with IONIS GHR-LRx in participants with acromegaly as add-on to somatostatin receptor ligands (SRL) therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Ionis Pharmaceuticals, Inc.

Treatments:

Somatostatin